EU Panel Sets Ambitious Big Data Workplan
An EU group has listed several ambitious projects to help EU regulators realize their cherished vision of using big data capabilities to support innovation and public health. But these proposals may take a backseat as COVID-19-related challenges continue.
You may also be interested in...
The European Medicines Agency will begin a pilot in 2021 to examine the practical aspects of undertaking patient-level data assessments during medicines evaluation and identify scenarios when such assessments might be useful.
The European Medicines Agency will use feedback from two workshops in September to clarify what data protection issues must be addressed to allow for the secondary use of health and medical data when it comes to developing, monitoring and evaluating medicines.
Regulators have produced yet another strategy outlining the challenges and next steps for the European drug regulatory network as the network prepares for a future characterized by rapid developments in science and technology, medicines access issues, supply chain weaknesses and emerging health threats.